Al18F-HER2-BCH PET/CT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Aged # 18 years old; ECOG 0 or 1;
• Is unresectable or metastatic;
• Patients with HER2 positive or suspicious positive tumors;
• was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane;
• Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
• Receives anti-HER2 ADC treatment
• Life expectancy \> 3 months
Locations
Other Locations
China
uEXPLORER total-body PET/CT scanner (United Imaging, China)
RECRUITING
Beijing
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2028-12-01
Participants
Target number of participants: 30
Treatments
Experimental: Al18F-HER2-BCH PET/CT in bladder cancer patients
Related Therapeutic Areas
Sponsors
Leads: Peking University Cancer Hospital & Institute